Skip to main content
. 2023 Aug 3;12:e79548. doi: 10.7554/eLife.79548

Appendix 2—table 41. Antidiabetic Non-user Cohort (Region=New York State) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users.

Region=NY Antidiabetic Non-users by BP: Unmatched Region=NY Antidiabetic Non-users by BP: Matched
All BP Non-user BP User p-value All BP Non-user BP User p-value
N % N % N % N % N % N %
All Patients 104,691 100.0% 95,416 91.1% 9,275 8.9% 18,288 100.0% 9,144 50.0% 9,144 50.0%
Age
≤20 455 0.4% 455 0.5% 0 0.0% <0.001 0 0.0% 0 0.0% 0 0.0% 1.00
21-40 6,164 5.9% 6,146 6.4% 18 0.2% 36 0.2% 18 0.2% 18 0.2%
41-50 10,440 10.0% 10,367 10.9% 73 0.8% 147 0.8% 74 0.8% 73 0.8%
51-60 24,369 23.3% 23,304 24.4% 1,065 11.5% 2,128 11.6% 1,064 11.6% 1,064 11.6%
61-70 28,819 27.5% 25,720 27.0% 3,099 33.4% 6,190 33.8% 3,097 33.9% 3,093 33.8%
71-80 24,311 23.2% 20,826 21.8% 3,485 37.6% 6,839 37.4% 3,419 37.4% 3,420 37.4%
≥81 10,133 9.7% 8,598 9.0% 1,535 16.5% 2,948 16.1% 1,472 16.1% 1,476 16.1%
Gender
Female 60,467 57.8% 52,194 54.7% 8,273 89.2% <0.001 16,291 89.1% 8,146 89.1% 8,145 89.1% 0.98
Male 44,224 42.2% 43,222 45.3% 1,002 10.8% 1,997 10.9% 998 10.9% 999 10.9%
Insurance
Commercial 32,100 30.7% 31,095 32.6% 1,005 10.8% <0.001 2,002 10.9% 1,000 10.9% 1,002 11.0% 1.00
Dual 2,196 2.1% 1,675 1.8% 521 5.6% 1,006 5.5% 502 5.5% 504 5.5%
Medicaid 27,925 26.7% 25,530 26.8% 2,395 25.8% 4,575 25.0% 2,289 25.0% 2,286 25.0%
Medicare 42,470 40.6% 37,116 38.9% 5,354 57.7% 10,705 58.5% 5,353 58.5% 5,352 58.5%
PCP Visit 2019
No 37,106 35.4% 34,553 36.2% 2,553 27.5% <0.001 5,039 27.6% 2,518 27.5% 2,521 27.6% 0.96
Yes 67,585 64.6% 60,863 63.8% 6,722 72.5% 13,249 72.4% 6,626 72.5% 6,623 72.4%
Continuous Outcomes
mean SD mean SD mean SD p-value mean SD mean SD mean SD p-value
CCI 1.32 1.79 1.32 1.79 1.37 1.81 0.007 1.37 1.78 1.36 1.78 1.37 1.79 0.92

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.